Gemifloxacin is efficacious against penicillin-resistant and quinolone-resistant pneumococci in experimental
Philippe Cottagnoud1, Fernando Acosta, Marianne Cottagnoud
1Department of Internal Medicine, Inselspital, University of Bern, 3010 Bern, Switzerland. pcottagn@insel.ch
Abstract:
In experimental rabbit meningitis, gemifloxacin penetrated inflamed meninges well (22 to 33%) and produced excellent bactericidal activity (change in log(10) [Deltalog(10)] CFU/ml/h, -0.68 +/- 0.30 [mean and standard deviation]), even superior to that of the standard regimen of ceftriaxone plus vancomycin (-0.49 +/- 0.09 deltalog(10) CFU/ml/h), in the treatment of meningitis due to a penicillin-resistant pneumococcal strain (MIC, 4 mg/liter). Even against a penicillin- and quinolone-resistant strain, gemifloxacin showed good bactericidal activity (-0.48 +/- 0.16 deltalog(10) CFU/ml/h). The excellent antibacterial activity of gemifloxacin was also confirmed by time-kill assays over 8 h in vitro.
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
Mechanism of Antibiotic Resistance in MRSA
Cryptococcal Meningitis
Atypical Pneumonia
Gene Regulation in Microbial Communities: Quorum Sensing
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
